rhIL-15 and anti-PD-L1 combination therapy expands a CXCR3+PD1-/low CD8 T cell subset in SIV-infected rhesus macaques.
The PD1/PD-L1 pathway contributes to the pathogenesis of HIV/SIV infection and blockade of this pathway may have potential to restore immune function and promote viral control/elimination. In this study, we combined a checkpoint inhibitor anti-PD-L1 (Avelumab) and recombinant human IL-15 (rhIL-15) in SIV infected rhesus macaques (RM). rhIL-15 was administered as continuous infusion in two cycles of ten days in the context of weekly administration of anti-PD-L1 (Avelumab) in SIV-infected RM receiving combination antiretroviral therapy (cART). Safety, immunological parameters and viral loads (VL) were monitored during the study. Administration of rhIL-15/anti-PD-L1 was safe and well tolerated. Treatment resulted in transient increases in proliferating (Ki67+) NK and CD8 T cells. In addition, treatment expanded a CXCR3+PD1-/low CD8 T cell subset with the ability to secrete cytokines. Despite these effects no changes in plasma viremia were observed after cART interruption. Expansion of the CXCR3+PD1-/low CD8 T cell subset with functional capacity and potential to traffic to sites of viral reservoirs in SIV-infected rhesus macaques, had no demonstrable effect on plasma viremia following cART interruption.